secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016625
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic Q2 2022 net loss $15.8M; cash $106.8M funds into 2024; three data readouts in H2 2022
--------------------------------------------------------------------------------

- Net loss $15.8M ($0.22 per share) vs $14.5M ($0.28) in Q2 2021; revenue $0.2M from Roche IBD collaboration.
- Cash, equivalents, and short-term investments $106.8M as of June 30, 2022; projected runway into 2024.
- Plan to report Phase 2 PKU data in H2 2022 and start Phase 3 in H1 2023; HCU Phase 1 and EH proof-of-concept data also due H2 2022.
- Named SYNB2081 (uric acid-lowering Synthetic Biotic for gout), second candidate from Ginkgo Bioworks partnership.
- R&D expenses $12.1M (up from $10.7M) and G&A $4.1M (flat YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000095017022016625/0000950170-22-016625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000095017022016625/sybx-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer